Strategies to overcome HIV drug resistance-current and future perspectives
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies to overcome HIV drug resistance-current and future perspectives
Authors
Keywords
-
Journal
Frontiers in Microbiology
Volume 14, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-02-16
DOI
10.3389/fmicb.2023.1133407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors
- (2022) Kohei Tsuji et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254
- (2022) Christoph D Spinner et al. CLINICAL INFECTIOUS DISEASES
- Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study
- (2022) Nicolas Margot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects
- (2022) Stefano Rusconi et al. PHARMACOLOGICAL RESEARCH
- Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
- (2022) Camilla Muccini et al. Drug Design Development and Therapy
- Novel RNase H Inhibitors Blocking RNA-directed Strand Displacement DNA Synthesis by HIV-1 Reverse Transcriptase
- (2022) Samara Martín-Alonso et al. JOURNAL OF MOLECULAR BIOLOGY
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
- (2022) Sorana Segal-Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species
- (2022) Xiao L. Chang et al. PLoS Pathogens
- Achieving virological control in pan-resistant HIV-1 infection: A case series
- (2022) Diana Canetti et al. EBioMedicine
- Dual targeting inhibitors for HIV-1 capsid and cyclophilin A: molecular docking, molecular dynamics, and quantum mechanics
- (2022) Fauad O. Obubeid et al. MOLECULAR SIMULATION
- Identification of 3-Oxindole Derivatives as Small Molecule HIV-1 Inhibitors Targeting Tat-Mediated Viral Transcription
- (2022) Dong-Eun Kim et al. MOLECULES
- Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
- (2021) Peter Ackerman et al. AIDS
- Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
- (2021) Ronald Rose et al. AIDS
- Lenacapavir: a first-in-class HIV-1 capsid inhibitor
- (2021) Hadas Dvory-Sobol et al. Current Opinion in HIV and AIDS
- Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection
- (2020) Hannah A. Blair DRUGS
- Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir
- (2020) Yagai Bouba et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
- (2020) Michael Kozal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cellular Factors Targeting HIV-1 Transcription and Viral RNA Transcripts
- (2020) Rayhane Nchioua et al. Viruses-Basel
- Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by Blocking Human TRIM5α Binding to the Viral Core
- (2020) Anastasia Selyutina et al. Cell Reports
- Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection
- (2020) Elias B. Chahine et al. ANNALS OF PHARMACOTHERAPY
- Clinical targeting of HIV capsid protein with a long-acting small molecule
- (2020) John O. Link et al. NATURE
- Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection
- (2020) Kayla Hiryak et al. ANNALS OF PHARMACOTHERAPY
- Burden of disease in PLWH harboring a multidrug resistant virus: data from PRESTIGIO Registry
- (2020) Laura Galli et al. Open Forum Infectious Diseases
- Long-acting drugs and formulations for the treatment and prevention of HIV infection
- (2020) Charles Flexner et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
- (2020) Samit R. Joshi et al. Pharmacology Research & Perspectives
- Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database
- (2020) Francesca Lombardi et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Soluble-type small-molecule CD4 mimics as HIV entry inhibitors
- (2019) Takuya Kobayakawa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption
- (2019) Chang-Yi Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat
- (2019) Chuan Li et al. Epigenetics & Chromatin
- Restriction of HIV-1 and other retroviruses by TRIM5
- (2019) Barbie K. Ganser-Pornillos et al. NATURE REVIEWS MICROBIOLOGY
- Inhibition of the thioredoxin system by PX-12 (1-methylpropyl 2-imidazolyl disulfide) impedes HIV-1 infection in TZM-bl cells
- (2019) Mathias Lundberg et al. Scientific Reports
- A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection
- (2019) Edwin DeJesus et al. CLINICAL INFECTIOUS DISEASES
- Determinants of Active-Site Inhibitor Interaction with HIV-1 RNase H
- (2019) Zhaoyong Xi et al. ACS Infectious Diseases
- Ibalizumab: First Global Approval
- (2018) Anthony Markham DRUGS
- 6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity
- (2018) Lei Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- 4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591
- (2018) Martin Markowitz et al. Current Opinion in HIV and AIDS
- Fostemsavir
- (2018) Pedro Cahn et al. Current Opinion in HIV and AIDS
- The return of PRO 140, a CCR5-directed mAb
- (2018) Melanie A. Thompson Current Opinion in HIV and AIDS
- Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
- (2018) Brinda Emu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Viral reverse transcriptases
- (2017) Luis Menéndez-Arias et al. VIRUS RESEARCH
- Thioredoxin (Trx1) regulates CD4 membrane domain localization and is required for efficient CD4-dependent HIV-1 entry
- (2016) Naazneen Moolla et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity
- (2016) Francesca Curreli et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Approved Antiviral Drugs over the Past 50 Years
- (2016) Erik De Clercq et al. CLINICAL MICROBIOLOGY REVIEWS
- Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe
- (2016) A Judd et al. HIV MEDICINE
- Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)
- (2016) Zhe Li Salie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclophilin A stabilizes the HIV-1 capsid through a novel non-canonical binding site
- (2016) Chuang Liu et al. Nature Communications
- Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation
- (2016) Mohamed Abdel-Mohsen et al. PLoS Pathogens
- The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition
- (2016) Kathrin Reiser et al. PLoS One
- Pharmacological intervention of HIV-1 maturation
- (2015) Dan Wang et al. Acta Pharmaceutica Sinica B
- A multivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and Dengue virus
- (2014) Norbert Varga et al. BIOMATERIALS
- Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
- (2013) Hasina Samji et al. PLoS One
- HIV-1 Assembly, Budding, and Maturation
- (2013) W. I. Sundquist et al. Cold Spring Harbor Perspectives in Medicine
- Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope
- (2012) Craig S. Pace et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Pattern Recognition Receptors in HIV Transmission
- (2012) Annelies W. Mesman et al. Frontiers in Immunology
- The Control of HIV Transcription: Keeping RNA Polymerase II on Track
- (2011) Melanie Ott et al. Cell Host & Microbe
- Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry
- (2011) S. Bi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Host factors mediating HIV-1 replication
- (2011) Brian M. Friedrich et al. VIRUS RESEARCH
- Discovery of a Small Molecule PDI Inhibitor That Inhibits Reduction of HIV-1 Envelope Glycoprotein gp120
- (2010) Maola M. G. Khan et al. ACS Chemical Biology
- Can the further clinical development of bevirimat be justified?
- (2010) Mark A Wainberg et al. AIDS
- The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit
- (2010) Jonathan Karn Current Opinion in HIV and AIDS
- Human glutaredoxin-1 catalyzes the reduction of HIV-1 gp120 and CD4 disulfides and its inhibition reduces HIV-1 replication
- (2008) Joeri Auwerx et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now